Shire is to bolster its burgeoning regenerative medicine division by acquiring substantially all of the assets of Pervasis Therapeutics in a deal that is reportedly worth as much as US$200 M. With the acquisition, Shire will gain Pervasis’ endothelial cell-based technology platform and its Phase II therapy Vascugel® for improving haemodialysis access in end-stage renal disease patients. The product will complement Dermagraft®, a treatment for diabetic foot ulcers that Shire obtained with its purchase of Advanced BioHealing.